{"id":397345,"date":"2020-12-10T08:34:08","date_gmt":"2020-12-10T13:34:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397345"},"modified":"2020-12-10T08:34:08","modified_gmt":"2020-12-10T13:34:08","slug":"nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/","title":{"rendered":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ORLANDO, Fla.<\/span>, <span class=\"xn-chron\">Dec. 10, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Nutriband Inc. (OTCQB: NTRB), a <span class=\"xn-location\">Nevada<\/span> corporation (the &#8220;Company&#8221;) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the &#8216;Abuse and Misuse Deterrent Transdermal Systems&#8217; patent application filed by its clinical subsidiary 4P Therapeutics.\u00a0 <\/p>\n<p>The patent underpins 4p Therapeutics&#8217; abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion to addresses the primary routes of abuse for opioid based transdermal patches.\u00a0 <\/p>\n<p>The Korean Intellectual Property Office is the latest to approve or allow the patent application following similar outcomes in <span class=\"xn-location\">Mexico<\/span>, <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">Russia<\/span>, <span class=\"xn-location\">Australia<\/span> and <span class=\"xn-location\">Japan<\/span>.<\/p>\n<p>\n        <b>About Nutriband Inc.<br \/><\/b>The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.<\/p>\n<p>The Company&#8217;s website is <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008334-1&amp;h=1410150349&amp;u=http%3A%2F%2Fwww.nutriband.com%2F&amp;a=www.nutriband.com\" rel=\"nofollow noopener noreferrer\">www.nutriband.com<\/a><\/u> and 4P&#8217;s website is <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008334-1&amp;h=2232539020&amp;u=http%3A%2F%2Fwww.4ptherapeutics.com%2F&amp;a=www.4PTherapeutics.com\" rel=\"nofollow noopener noreferrer\">www.4PTherapeutics.com<\/a><\/u>.\u00a0 Any material contained in or derived from the Company&#8217;s or 4P&#8217;s websites or any other website is not part of this press release.<\/p>\n<p>\n        <b>About Our Forward-Looking Statements<br \/><\/b>Certain statements contained in this press release, including, without limitation, statements containing the words &#8221;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects&#8221; and words of similar import, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company&#8217;s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company&#8217;s ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in\u00a0the United States\u00a0and to obtain any other regulatory approval necessary to market any product in other countries, including countries in\u00a0Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company&#8217;s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized development stage company that does not have a product that can be marketed, and the risks contained under &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Form 10-K for the year ended\u00a0January 31, 2020\u00a0and under &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations&#8221; in the Company&#8217;s Form 10-Q for the three months ended\u00a0July 31, 2020, and the Company&#8217;s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.<\/p>\n<p>For more information, contact:<br \/><span class=\"xn-person\">Victor Roberts<\/span><br \/>Red Chip Companies<br \/>407-571-0909 <br \/><u><a target=\"_blank\" href=\"mailto:261074@email4pr.com\" rel=\"nofollow noopener noreferrer\">261074@email4pr.com<\/a><\/u>\u00a0 <br \/><u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008334-1&amp;h=2147165188&amp;u=http%3A%2F%2Fwww.redchip.com%2F&amp;a=www.redchip.com\" rel=\"nofollow noopener noreferrer\">www.redchip.com<\/a><\/u>\u00a0 <\/p>\n<p>\n        <span class=\"xn-person\">Gerald Weigel<\/span><br \/>\n        <br \/>Public Relations Principal<br \/>Nutriband Inc.<br \/>Nutriband Office: 407-377-6695<br \/>Direct: 419-304-6300 <br \/><u><a target=\"_blank\" href=\"mailto:261074@email4pr.com\" rel=\"nofollow noopener noreferrer\">261074@email4pr.com<\/a><\/u>\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent-301189919.html\">http:\/\/www.prnewswire.com\/news-releases\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent-301189919.html<\/a><\/p>\n<p>SOURCE  Nutriband Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH19259&amp;Transmission_Id=202012100831PR_NEWS_USPR_____PH19259&amp;DateId=20201210\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ORLANDO, Fla., Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the &#8220;Company&#8221;) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the &#8216;Abuse and Misuse Deterrent Transdermal Systems&#8217; patent application filed by its clinical subsidiary 4P Therapeutics.\u00a0 The patent underpins 4p Therapeutics&#8217; abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion to addresses the primary routes of abuse for opioid based transdermal patches.\u00a0 The Korean Intellectual Property Office is the latest to approve or allow the patent application following similar outcomes in Mexico, Europe, Russia, Australia and Japan. About Nutriband Inc.The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397345","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#039;Abuse and Misuse Deterrent Transdermal System&#039; Patent - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#039;Abuse and Misuse Deterrent Transdermal System&#039; Patent - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ORLANDO, Fla., Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the &#8220;Company&#8221;) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the &#8216;Abuse and Misuse Deterrent Transdermal Systems&#8217; patent application filed by its clinical subsidiary 4P Therapeutics.\u00a0 The patent underpins 4p Therapeutics&#8217; abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion to addresses the primary routes of abuse for opioid based transdermal patches.\u00a0 The Korean Intellectual Property Office is the latest to approve or allow the patent application following similar outcomes in Mexico, Europe, Russia, Australia and Japan. About Nutriband Inc.The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under &hellip; Continue reading &quot;Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T13:34:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent\",\"datePublished\":\"2020-12-10T13:34:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH19259&amp;sd=2020-12-10\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/\",\"name\":\"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its 'Abuse and Misuse Deterrent Transdermal System' Patent - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH19259&amp;sd=2020-12-10\",\"datePublished\":\"2020-12-10T13:34:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH19259&amp;sd=2020-12-10\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH19259&amp;sd=2020-12-10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its 'Abuse and Misuse Deterrent Transdermal System' Patent - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/","og_locale":"en_US","og_type":"article","og_title":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its 'Abuse and Misuse Deterrent Transdermal System' Patent - Market Newsdesk","og_description":"PR Newswire ORLANDO, Fla., Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the &#8220;Company&#8221;) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the &#8216;Abuse and Misuse Deterrent Transdermal Systems&#8217; patent application filed by its clinical subsidiary 4P Therapeutics.\u00a0 The patent underpins 4p Therapeutics&#8217; abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion to addresses the primary routes of abuse for opioid based transdermal patches.\u00a0 The Korean Intellectual Property Office is the latest to approve or allow the patent application following similar outcomes in Mexico, Europe, Russia, Australia and Japan. About Nutriband Inc.The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under &hellip; Continue reading \"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T13:34:08+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent","datePublished":"2020-12-10T13:34:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/","name":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its 'Abuse and Misuse Deterrent Transdermal System' Patent - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10","datePublished":"2020-12-10T13:34:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH19259&amp;sd=2020-12-10"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-receives-notice-of-allowance-from-korean-intellectual-property-office-kipo-for-its-abuse-and-misuse-deterrent-transdermal-system-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its &#8216;Abuse and Misuse Deterrent Transdermal System&#8217; Patent"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397345"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}